Obexelimab Shows Efficacy in Reducing Flares for IgG4-Related Disease

Subcutaneous obexelimab significantly reduced the risk of flares in patients with IgG4-related disease (IgG4-RD) by 56% compared to a placebo over 52 weeks, according to data from the phase 3 INDIGO trial. The findings, presented at the 2026 EULAR Congress, suggest that this bifunctional monoclonal antibody may offer a new therapeutic path for managing the chronic, relapsing nature of the condition.

How Obexelimab Works in IgG4-Related Disease

IgG4-related disease is characterized by immune-mediated inflammation that often leads to organ damage and requires long-term management. Current standard treatments, including glucocorticoids and B-cell depletion therapies, often fail to prevent recurrent flares. Obexelimab (Zenas Biopharma) functions differently by co-engaging CD19 and the inhibitory receptor FcRIIb (CD32b). According to researchers, this dual action effectively inhibits B-cell activation and function, addressing the underlying immune dysregulation rather than simply depleting cell populations.

Clinical Trial Results and Primary Endpoints

The INDIGO trial was a global, multicenter, randomized, double-blind, placebo-controlled study involving 194 adult participants who met the 2019 American College of Rheumatology/EULAR classification criteria. Participants were split evenly, with 97 receiving 250 mg of subcutaneous obexelimab weekly and 97 receiving a placebo, following a glucocorticoid-induced remission period.

The study met its primary endpoint, with 26.8% of the obexelimab group experiencing a flare requiring rescue therapy, compared to 54.6% in the placebo group (HR = 0.443; P = .0005). Beyond the primary endpoint, the drug also demonstrated statistically significant improvements in secondary measures, including:

• Time to first investigator-determined flare (P = .0001).
• Total number of investigator- and independent committee-determined flares (P = .0008).
• Proportion of patients achieving complete remission (P = .0049).
• Reduction in cumulative glucocorticoid rescue therapy use (P = .0042).

Safety Profile and Adverse Events

Safety data from the INDIGO trial indicated that obexelimab was generally well-tolerated. Treatment-emergent adverse events were reported in 97.9% of the obexelimab group and 95.9% of the placebo group. Notably, the study observed lower rates of grade 3 or greater adverse events in the obexelimab arm (11.3%) compared to the placebo arm (23.7%). Serious adverse events also occurred less frequently in those receiving the study drug (10.3%) than in the placebo group (18.6%). Infection rates were 53.6% for obexelimab and 62.9% for placebo, with no new safety signals identified during the 52-week study period.

Current Treatment Landscape

The management of IgG4-RD remains a clinical challenge due to the high frequency of relapses. Historically, clinicians have relied on glucocorticoids for initial control, but these carry significant long-term side effects. While B-cell depletion therapies have been used, many patients continue to experience flares. The INDIGO trial results, as presented by Dr. Emanuel Della Torre of the IRCCS San Raffaele Scientific Institute, provide the first evidence of a subcutaneous B-cell inhibiting agent showing efficacy in this patient population. These results may signal a shift in how rheumatologists approach long-term maintenance therapy for IgG4-RD, moving away from reliance on high-dose steroids.

Key Takeaways

• Study Scope: A 52-week, phase 3, randomized trial of 194 patients.
• Primary Outcome: A 56% reduction in flare risk for those treated with obexelimab.
• Safety: No new safety signals; serious adverse events were lower in the treatment group than the placebo group.
• Mechanism: Unlike standard B-cell depletion, obexelimab inhibits B-cell function by targeting CD19 and FcRIIb.